Paper Details

  1. Home
  2. Paper Details

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Author:

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Clopidogrel is a new thienopyridine derivative that inhibits platelet aggregation induced by adenosine diphosphate. It may be an effective alternative to aspirin and ticlopidine for the prevention of thrombotic events.
Paper Details　
Original Abstract of the Article :
Many clinical trials have evaluated the benefit of long-term use of antiplatelet drugs in reducing the risk of clinical thrombotic events. Aspirin and ticlopidine have been shown to be effective, but both have potentially serious adverse effects. Clopidogrel, a new thienopyridine derivative similar ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/s0140-6736(96)09457-3

データ提供：米国国立医学図書館（NLM）

A Quest for Better Antiplatelet Therapy: Comparing Clopidogrel and Aspirin in Patients at Risk of Ischemic Events

Cardiovascular disease is a formidable adversary, affecting millions worldwide. This research focuses on a key aspect of preventing ischemic events, exploring the effectiveness of two antiplatelet drugs, clopidogrel and aspirin, in reducing the risk of these events. The study examines the efficacy of these drugs in a randomized, blinded trial, comparing their ability to prevent ischemic events in patients with a high risk for these events. This research aims to provide valuable insights into the optimal choice of antiplatelet therapy for preventing ischemic events.

A Head-to-Head Comparison: Evaluating Clopidogrel and Aspirin in the CAPRIE Trial

The study, known as the CAPRIE trial, involved a large group of patients at risk for ischemic events. The researchers randomly assigned patients to receive either clopidogrel or aspirin and monitored their outcomes over time. The results of the CAPRIE trial demonstrated that clopidogrel was more effective than aspirin in reducing the risk of ischemic events, providing strong evidence that clopidogrel may be a superior choice for preventing ischemic events in high-risk patients.

Making Informed Choices: Selecting the Right Antiplatelet Therapy

This study provides valuable guidance for clinicians treating patients at risk for ischemic events. By comparing the efficacy of clopidogrel and aspirin, the study underscores the importance of selecting the most appropriate antiplatelet therapy based on individual patient factors and risk profiles. Further research is needed to explore the potential long-term benefits and risks of clopidogrel in preventing ischemic events and to determine its optimal role in cardiovascular disease management.

Dr.Camel's Conclusion

The CAPRIE trial provides compelling evidence that clopidogrel is more effective than aspirin in reducing the risk of ischemic events in high-risk patients. This research underscores the importance of selecting the most appropriate antiplatelet therapy based on individual patient needs, helping to improve outcomes for patients at risk for cardiovascular events. The findings of this study offer a valuable contribution to the ongoing effort to prevent ischemic events and improve the health of individuals at risk for cardiovascular disease.

Date :
  1. Date Completed 1996-12-17
  2. Date Revised 2023-10-24
Further Info :

Pubmed ID

8918275

DOI: Digital Object Identifier

10.1016/s0140-6736(96)09457-3

Related Literature

Article Analysis
・Effects of clopidogrel
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.